{
    "nct_id": "NCT02526823",
    "official_title": "Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma",
    "criteria": {
        "raw_text": "Inclusion Criteria:\n\n1. Primary B-NHL, PTCL (ALK+ anaplastic large cell lymphoma and NK(natural killer cell )/T cell lymphoma were excluded) or HL patients confirmed by histopathology;\n2. Ages ≥18 years old, \\< 80 years old;\n3. ECOG (Eastern Cooperative Oncology Group）score: 0-2\n4. At least one measurable lesion;\n5. Expected survival time≥3 months;\n6. Liver function: transaminase≤2.5× upper limit of normal value，bilirubin≤1.5×upper limit of normal value;\n7. Renal function: serum creatinine is 44-133 mmol/L;\n8. Routine blood test：WBC≥3.0×109/L，Neutrophils≥1.5×109/L，Hb≥100g/L，Platelet≥80×109/L； LVEF≥50%;\n9. New York Heart Association (NYHA) heart function classification is I-II grade\n10. signed informed consent.\n\nExclusion Criteria:\n\n1. Patients with severe complications or severe infection;\n2. Invasion of central nervous system;\n3. Patients with severe heart disease history, including ventricular tachycardia (VT), atrial fibrillation (AF), heart block, myocardial infarction (MI), congestive heart failure (CHF), coronary heart disease patients needed therapy;\n4. patients with severe allergic constitution, or those who are allergic to or intolerant of drug composition in chemotherapy regimens; with other malignant tumors in the past 5 years;\n5. patients received doxorubicin therapy, total cumulative dose of adriamycin was more than 300 mg/m2, total cumulative dose of epirubicin was more than 450 mg/m2;\n6. Patients participate in other clinical studies;\n7. Other patients who are not suitable for the study.\n\nsex: ALL\n\nminimumAge: 18 Years\n\nmaximumAge: 80 Years\n\nstdAges: ['ADULT', 'OLDER_ADULT']",
        "inclusion": "1. Primary B-NHL, PTCL (ALK+ anaplastic large cell lymphoma and NK(natural killer cell )/T cell lymphoma were excluded) or HL patients confirmed by histopathology;\n2. Ages ≥18 years old, < 80 years old;\n3. ECOG (Eastern Cooperative Oncology Group）score: 0-2\n4. At least one measurable lesion;\n5. Expected survival time≥3 months;\n6. Liver function: transaminase≤2.5× upper limit of normal value，bilirubin≤1.5×upper limit of normal value;\n7. Renal function: serum creatinine is 44-133 mmol/L;\n8. Routine blood test：WBC≥3.0×109/L，Neutrophils≥1.5×109/L，Hb≥100g/L，Platelet≥80×109/L； LVEF≥50%;\n9. New York Heart Association (NYHA) heart function classification is I-II grade\n10. signed informed consent.",
        "exclusion": "1. Patients with severe complications or severe infection;\n2. Invasion of central nervous system;\n3. Patients with severe heart disease history, including ventricular tachycardia (VT), atrial fibrillation (AF), heart block, myocardial infarction (MI), congestive heart failure (CHF), coronary heart disease patients needed therapy;\n4. patients with severe allergic constitution, or those who are allergic to or intolerant of drug composition in chemotherapy regimens; with other malignant tumors in the past 5 years;\n5. patients received doxorubicin therapy, total cumulative dose of adriamycin was more than 300 mg/m2, total cumulative dose of epirubicin was more than 450 mg/m2;\n6. Patients participate in other clinical studies;\n7. Other patients who are not suitable for the study."
    }
}